HCV / Hepatitis

A retrospective study found hepatitis C reinfection rates high are in HIV-positive men who have sex with men from four western European countries.

A recent study from US researchers suggests that liver disease severity and treatment costs for people with hepatitis C (HCV) vary depending on a patient’s genotype.

Regulus Therapeutic’s hepatitis C drug, RG-101, has been on clinical hold since mid-2016; FDA calls for additional data before hold is lifted.

Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses potential strategies to reduce incidence of acute kidney injuries due to vancomycin and pip/tazo combination therapy.

The retrospective study included a cohort of patients from six countries across Europe who were diagnosed with HCV and received daclatasvir during the Named Patient Program.

A new study finds that cancer incidence in individuals with cirrhosis is lower than originally believed—at most, about 4%.

According to the Belgian researchers, Sofosbuvir in combination with simeprevir with or without ribarivirn was found to be well-tolerated and efficacious.

In a review article published in Rheumatic Disease Clinics of North America, researchers discuss the main rheumatologic diseases associated with chronic HCV infection, and how DAAs have affected these extrahepatic manifestations.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), discusses the CDC’s HCV universal birth cohort testing program.

A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.

A report warns that liver failure might be associated with nine new direct-acting antivirals (DAA).

A group of researchers recently published a study in JAMA, examining conflicts of interest (COIs) among committee members who set hepatitis C (HCV) and cholesterol management guidelines. They found that there, in fact, were COIs among committee members setting HCV management guidelines.

The European Medicines Agency has fully validated Gilead’s SOf/VEL/VOX regimen to treat hepatitis C (HCV).

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains that hepatitis C infection awareness has been on the rise in the United States.

Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of patients in a study published in Neurology in December 2016.

Researchers conducted a post hoc analysis to learn whether or not the length of time it took to attain initial viral suppression is related to sustained virologic response (SVR) rates for patients receiving the so-call 3D treatment, with or without ribavirin.

Insurance companies are denying members coverage to expensive drugs, like Harvoni, and those infected with HCV are filing lawsuits.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, discusses the importance of new medications to treat hepatitis C.

A new project aims to develop and assess new hepatitis C vaccination strategies in an effort to improve treatment.

Researchers offer more insight on the role of IFN-I and find a potential therapeutic target that may be able to protect against chronic viral infections.

New research from the Medical University of Vienna has made a connect between blood infections and an increased risk of arteriosclerosis.

In a phase 3 clinical trial, Japanese patients with chronic hepatitis C (HCV) infection without liver cirrhosis were able to achieve high sustained viral response rates after taking an investigational HCV drug from AbbVie.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains why it’s important for individuals to know that they are infected with hepatitis C, although they may be asymptomatic.

A new biotechnology company, Vir Biotechnology, is gunning for bear in the fight against infectious diseases and boasting a roster of heavy hitters in the industry.

Despite the fact that an increasingly large portion of the hepatitis C (HCV)-infected population successfully achieves a cure for the infection, called sustained viral response (SVR), this population still deals with increased mortality rates.